Is Realty Income the Best Dividend Stock to Buy Long-Term?
Realty Income (NYSE:O) is a longstanding real estate investment trust…
Sell
36
TMO Quote, Financials, Valuation and Earnings
Last price:
$427.09
Seasonality move
:
4.88%
Day range:
$415.31 - $448.60
52-week range:
$409.85 - $627.88
Dividend yield:
0.35%
P/E ratio:
27.44x
P/S ratio:
4.06x
P/B ratio:
3.45x
Volume:
4.6M
Avg. volume:
2.1M
1-year change:
-23.02%
Market cap:
$171.1B
Revenue:
$42.9B
EPS (TTM):
$16.53
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
TMO
Thermo Fisher Scientific
|
$10.2B | $5.10 | 2.21% | 38.28% | $643.08 |
|
APDN
Applied DNA Sciences
|
$1.2M | -$3.00 | 27.47% | -98.87% | -- |
|
FONR
Fonar
|
-- | -- | -- | -- | -- |
|
PRPH
ProPhase Labs
|
$2.5M | -$0.18 | -32.58% | -48.57% | $13.80 |
|
VCYT
Veracyte
|
$110.5M | $0.20 | 14.14% | -93.75% | $43.70 |
|
XWEL
XWELL
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
TMO
Thermo Fisher Scientific
|
$453.55 | $643.08 | $171.1B | 27.44x | $0.43 | 0.35% | 4.06x |
|
APDN
Applied DNA Sciences
|
$1.18 | -- | $1.3M | -- | $0.00 | 0% | 0.07x |
|
FONR
Fonar
|
$12.56 | -- | $79.5M | 10.92x | $0.00 | 0% | 0.79x |
|
PRPH
ProPhase Labs
|
$0.29 | $13.80 | $12.1M | -- | $0.00 | 0% | 0.88x |
|
VCYT
Veracyte
|
$32.62 | $43.70 | $2.5B | 108.73x | $0.00 | 0% | 5.69x |
|
XWEL
XWELL
|
$0.74 | -- | $3.9M | -- | $0.00 | 0% | 0.10x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
TMO
Thermo Fisher Scientific
|
38.68% | 0.768 | 15.78% | 1.14x |
|
APDN
Applied DNA Sciences
|
-- | 5.762 | -- | 4.28x |
|
FONR
Fonar
|
0.03% | 1.790 | 0.07% | 10.85x |
|
PRPH
ProPhase Labs
|
31.06% | -3.205 | 37.21% | 1.12x |
|
VCYT
Veracyte
|
-- | 3.539 | -- | 4.27x |
|
XWEL
XWELL
|
-- | -1.288 | -- | 1.72x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
TMO
Thermo Fisher Scientific
|
$4.8B | $2.2B | 7.7% | 13.27% | 19.82% | $2.8B |
|
APDN
Applied DNA Sciences
|
$684.1K | -$3M | -113.07% | -113.07% | -247.7% | -$3.4M |
|
FONR
Fonar
|
$9.7M | $2.4M | 4.95% | 4.95% | 11.92% | $1.5M |
|
PRPH
ProPhase Labs
|
-$165K | -$7.9M | -47.22% | -59.59% | -252.29% | -$4.2M |
|
VCYT
Veracyte
|
$78.8M | $6M | 2.14% | 2.14% | 2.9% | $20.4M |
|
XWEL
XWELL
|
$2.1M | -$4.6M | -71.82% | -71.82% | -54.82% | -$3.8M |
Thermo Fisher Scientific vs. Competitors
-
Which has Higher Returns TMO or APDN?
Applied DNA Sciences has a net margin of 16.06% compared to Thermo Fisher Scientific's net margin of -220.57%. Thermo Fisher Scientific's return on equity of 13.27% beat Applied DNA Sciences's return on equity of -113.07%.
Company Gross Margin Earnings Per Share Invested Capital TMOThermo Fisher Scientific42.32% $4.78 $80.9B APDNApplied DNA Sciences57.17% -$28.00 $12.5M -
What do Analysts Say About TMO or APDN?
Thermo Fisher Scientific has a consensus price target of $643.08, signalling upside risk potential of 42.93%. On the other hand Applied DNA Sciences has an analysts' consensus of -- which suggests that it could grow by 127018.64%. Given that Applied DNA Sciences has higher upside potential than Thermo Fisher Scientific, analysts believe Applied DNA Sciences is more attractive than Thermo Fisher Scientific.
Company Buy Ratings Hold Ratings Sell Ratings TMOThermo Fisher Scientific18 6 0 APDNApplied DNA Sciences0 1 0 -
Is TMO or APDN More Risky?
Thermo Fisher Scientific has a beta of 0.865, which suggesting that the stock is 13.532% less volatile than S&P 500. In comparison Applied DNA Sciences has a beta of 0.856, suggesting its less volatile than the S&P 500 by 14.433%.
-
Which is a Better Dividend Stock TMO or APDN?
Thermo Fisher Scientific has a quarterly dividend of $0.43 per share corresponding to a yield of 0.35%. Applied DNA Sciences offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Thermo Fisher Scientific pays 9.2% of its earnings as a dividend. Applied DNA Sciences pays out -- of its earnings as a dividend. Thermo Fisher Scientific's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios TMO or APDN?
Thermo Fisher Scientific quarterly revenues are $11.4B, which are larger than Applied DNA Sciences quarterly revenues of $1.2M. Thermo Fisher Scientific's net income of $1.8B is higher than Applied DNA Sciences's net income of -$2.6M. Notably, Thermo Fisher Scientific's price-to-earnings ratio is 27.44x while Applied DNA Sciences's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Thermo Fisher Scientific is 4.06x versus 0.07x for Applied DNA Sciences. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TMOThermo Fisher Scientific4.06x 27.44x $11.4B $1.8B APDNApplied DNA Sciences0.07x -- $1.2M -$2.6M
-
Which has Higher Returns TMO or FONR?
Fonar has a net margin of 16.06% compared to Thermo Fisher Scientific's net margin of 7.87%. Thermo Fisher Scientific's return on equity of 13.27% beat Fonar's return on equity of 4.95%.
Company Gross Margin Earnings Per Share Invested Capital TMOThermo Fisher Scientific42.32% $4.78 $80.9B FONRFonar39.03% $0.29 $159M -
What do Analysts Say About TMO or FONR?
Thermo Fisher Scientific has a consensus price target of $643.08, signalling upside risk potential of 42.93%. On the other hand Fonar has an analysts' consensus of -- which suggests that it could fall by --. Given that Thermo Fisher Scientific has higher upside potential than Fonar, analysts believe Thermo Fisher Scientific is more attractive than Fonar.
Company Buy Ratings Hold Ratings Sell Ratings TMOThermo Fisher Scientific18 6 0 FONRFonar0 0 0 -
Is TMO or FONR More Risky?
Thermo Fisher Scientific has a beta of 0.865, which suggesting that the stock is 13.532% less volatile than S&P 500. In comparison Fonar has a beta of 1.167, suggesting its more volatile than the S&P 500 by 16.736%.
-
Which is a Better Dividend Stock TMO or FONR?
Thermo Fisher Scientific has a quarterly dividend of $0.43 per share corresponding to a yield of 0.35%. Fonar offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Thermo Fisher Scientific pays 9.2% of its earnings as a dividend. Fonar pays out -- of its earnings as a dividend. Thermo Fisher Scientific's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios TMO or FONR?
Thermo Fisher Scientific quarterly revenues are $11.4B, which are larger than Fonar quarterly revenues of $25M. Thermo Fisher Scientific's net income of $1.8B is higher than Fonar's net income of $2M. Notably, Thermo Fisher Scientific's price-to-earnings ratio is 27.44x while Fonar's PE ratio is 10.92x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Thermo Fisher Scientific is 4.06x versus 0.79x for Fonar. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TMOThermo Fisher Scientific4.06x 27.44x $11.4B $1.8B FONRFonar0.79x 10.92x $25M $2M
-
Which has Higher Returns TMO or PRPH?
ProPhase Labs has a net margin of 16.06% compared to Thermo Fisher Scientific's net margin of -209.38%. Thermo Fisher Scientific's return on equity of 13.27% beat ProPhase Labs's return on equity of -59.59%.
Company Gross Margin Earnings Per Share Invested Capital TMOThermo Fisher Scientific42.32% $4.78 $80.9B PRPHProPhase Labs-5.25% -$0.35 $55.3M -
What do Analysts Say About TMO or PRPH?
Thermo Fisher Scientific has a consensus price target of $643.08, signalling upside risk potential of 42.93%. On the other hand ProPhase Labs has an analysts' consensus of $13.80 which suggests that it could grow by 4658.62%. Given that ProPhase Labs has higher upside potential than Thermo Fisher Scientific, analysts believe ProPhase Labs is more attractive than Thermo Fisher Scientific.
Company Buy Ratings Hold Ratings Sell Ratings TMOThermo Fisher Scientific18 6 0 PRPHProPhase Labs0 0 0 -
Is TMO or PRPH More Risky?
Thermo Fisher Scientific has a beta of 0.865, which suggesting that the stock is 13.532% less volatile than S&P 500. In comparison ProPhase Labs has a beta of -0.562, suggesting its less volatile than the S&P 500 by 156.182%.
-
Which is a Better Dividend Stock TMO or PRPH?
Thermo Fisher Scientific has a quarterly dividend of $0.43 per share corresponding to a yield of 0.35%. ProPhase Labs offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Thermo Fisher Scientific pays 9.2% of its earnings as a dividend. ProPhase Labs pays out -- of its earnings as a dividend. Thermo Fisher Scientific's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios TMO or PRPH?
Thermo Fisher Scientific quarterly revenues are $11.4B, which are larger than ProPhase Labs quarterly revenues of $3.1M. Thermo Fisher Scientific's net income of $1.8B is higher than ProPhase Labs's net income of -$6.6M. Notably, Thermo Fisher Scientific's price-to-earnings ratio is 27.44x while ProPhase Labs's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Thermo Fisher Scientific is 4.06x versus 0.88x for ProPhase Labs. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TMOThermo Fisher Scientific4.06x 27.44x $11.4B $1.8B PRPHProPhase Labs0.88x -- $3.1M -$6.6M
-
Which has Higher Returns TMO or VCYT?
Veracyte has a net margin of 16.06% compared to Thermo Fisher Scientific's net margin of 4.31%. Thermo Fisher Scientific's return on equity of 13.27% beat Veracyte's return on equity of 2.14%.
Company Gross Margin Earnings Per Share Invested Capital TMOThermo Fisher Scientific42.32% $4.78 $80.9B VCYTVeracyte66.39% $0.06 $1.2B -
What do Analysts Say About TMO or VCYT?
Thermo Fisher Scientific has a consensus price target of $643.08, signalling upside risk potential of 42.93%. On the other hand Veracyte has an analysts' consensus of $43.70 which suggests that it could grow by 36.42%. Given that Thermo Fisher Scientific has higher upside potential than Veracyte, analysts believe Thermo Fisher Scientific is more attractive than Veracyte.
Company Buy Ratings Hold Ratings Sell Ratings TMOThermo Fisher Scientific18 6 0 VCYTVeracyte7 2 1 -
Is TMO or VCYT More Risky?
Thermo Fisher Scientific has a beta of 0.865, which suggesting that the stock is 13.532% less volatile than S&P 500. In comparison Veracyte has a beta of 2.032, suggesting its more volatile than the S&P 500 by 103.174%.
-
Which is a Better Dividend Stock TMO or VCYT?
Thermo Fisher Scientific has a quarterly dividend of $0.43 per share corresponding to a yield of 0.35%. Veracyte offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Thermo Fisher Scientific pays 9.2% of its earnings as a dividend. Veracyte pays out -- of its earnings as a dividend. Thermo Fisher Scientific's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios TMO or VCYT?
Thermo Fisher Scientific quarterly revenues are $11.4B, which are larger than Veracyte quarterly revenues of $118.6M. Thermo Fisher Scientific's net income of $1.8B is higher than Veracyte's net income of $5.1M. Notably, Thermo Fisher Scientific's price-to-earnings ratio is 27.44x while Veracyte's PE ratio is 108.73x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Thermo Fisher Scientific is 4.06x versus 5.69x for Veracyte. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TMOThermo Fisher Scientific4.06x 27.44x $11.4B $1.8B VCYTVeracyte5.69x 108.73x $118.6M $5.1M
-
Which has Higher Returns TMO or XWEL?
XWELL has a net margin of 16.06% compared to Thermo Fisher Scientific's net margin of -56.4%. Thermo Fisher Scientific's return on equity of 13.27% beat XWELL's return on equity of -71.82%.
Company Gross Margin Earnings Per Share Invested Capital TMOThermo Fisher Scientific42.32% $4.78 $80.9B XWELXWELL24.38% -$0.99 $14.8M -
What do Analysts Say About TMO or XWEL?
Thermo Fisher Scientific has a consensus price target of $643.08, signalling upside risk potential of 42.93%. On the other hand XWELL has an analysts' consensus of -- which suggests that it could grow by 844.67%. Given that XWELL has higher upside potential than Thermo Fisher Scientific, analysts believe XWELL is more attractive than Thermo Fisher Scientific.
Company Buy Ratings Hold Ratings Sell Ratings TMOThermo Fisher Scientific18 6 0 XWELXWELL0 0 0 -
Is TMO or XWEL More Risky?
Thermo Fisher Scientific has a beta of 0.865, which suggesting that the stock is 13.532% less volatile than S&P 500. In comparison XWELL has a beta of 2.106, suggesting its more volatile than the S&P 500 by 110.579%.
-
Which is a Better Dividend Stock TMO or XWEL?
Thermo Fisher Scientific has a quarterly dividend of $0.43 per share corresponding to a yield of 0.35%. XWELL offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Thermo Fisher Scientific pays 9.2% of its earnings as a dividend. XWELL pays out -- of its earnings as a dividend. Thermo Fisher Scientific's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios TMO or XWEL?
Thermo Fisher Scientific quarterly revenues are $11.4B, which are larger than XWELL quarterly revenues of $8.4M. Thermo Fisher Scientific's net income of $1.8B is higher than XWELL's net income of -$4.8M. Notably, Thermo Fisher Scientific's price-to-earnings ratio is 27.44x while XWELL's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Thermo Fisher Scientific is 4.06x versus 0.10x for XWELL. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TMOThermo Fisher Scientific4.06x 27.44x $11.4B $1.8B XWELXWELL0.10x -- $8.4M -$4.8M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Archer Aviation a Buy, Sell or Hold?
Vertical takeoff and landing (eVTOL) aircraft sound futuristic but that’s…
Down 50%, Is Dell Technologies a Buy?
Dell (NYSE:DELL)’s share price has been on a roller coaster…
Stock Ideas
Sell
45
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Buy
53
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 39x
Alerts
Sell
18
BULZ alert for Apr 11
MicroSectors Solactive FANG & Innov 3X Levd ETN [BULZ] is down 15.35% over the past day.
Sell
31
TECS alert for Apr 10
Direxion Daily Technology Bear 3x Shares [TECS] is up 12.66% over the past day.
Sell
48
FNGA alert for Apr 10
MicroSectors FANG+ Index 3X Leveraged ETN [FNGA] is down 13.3% over the past day.
